Functional ability and quality of life in critical illness survivors with intensive care unit acquired weakness: A secondary analysis of a randomised controlled trial. by Eggmann, Sabrina et al.
RESEARCH ARTICLE
Functional ability and quality of life in critical
illness survivors with intensive care unit
acquired weakness: A secondary analysis of a
randomised controlled trial
Sabrina EggmannID1,2*, Gere LuderID1, Martin L. Verra1, Irina Irincheeva3, Caroline H.
G. Bastiaenen2, Stephan M. Jakob4
1 Department of Physiotherapy, Insel Group, Inselspital, Bern University Hospital, Bern, Switzerland,
2 Department of Epidemiology, Research Line Functioning and Rehabilitation CAPHRI, Maastricht
University, Maastricht, the Netherlands, 3 CTU Bern, University of Bern, Bern, Switzerland, 4 Department of
Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
* sabrina.eggmann@insel.ch
Abstract
Introduction
Intensive care unit acquired weakness (ICUAW) may contribute to functional disability
in ICU survivors, yet performance-based data for general ICU patients are lacking.
This study explored functional outcomes of (1) and risk factors for (2) weakness at ICU
discharge.
Methods
Data from a randomised controlled trial that investigated two early exercise regimes in previ-
ously independent, ventilated adults (n = 115) without any significant outcome-differences
were used for the present analysis. ICUAW was clinically diagnosed in cooperative partici-
pants (n = 83) at ICU discharge with the Medical Research Council sum-score (MRC-SS)
using a cut-off <48 for moderate or <36 for severe weakness. Primary outcomes were the 6-
Minute Walk Test and Functional Independence Measure at hospital discharge. Secondary
outcomes included health-related quality of life after six months. Risk factors during the ICU
stay were explored for their effect on MRC-SS with linear regression.
Results
Functional outcomes and length of hospital stay significantly differed in patients with severe,
moderate to no weakness (6-Minute Walk test: p = 0.013; 110m [IQR 75–240], 196m [90–
324.25], 222.5m [129–378.75], Functional Independence Measure: p = 0.001; 91[IQR 68–
101], 113[102.5–118.5], 112[97–123], length of stay after ICU discharge: p = 0.008; 20.9d
[IQR 15.83–30.73], 16.86d [13.07–27.10], 11.16d [7.35–19.74]). However, after six months
participants had similar values for quality of life regardless of their strength at ICU discharge
(Short-Form 36 sum-scores physical health: p = 0.874, mental health: p = 0.908). In-bed
PLOS ONE
PLOS ONE | https://doi.org/10.1371/journal.pone.0229725 March 4, 2020 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Eggmann S, Luder G, Verra ML,
Irincheeva I, Bastiaenen CHG, Jakob SM (2020)
Functional ability and quality of life in critical illness
survivors with intensive care unit acquired
weakness: A secondary analysis of a randomised
controlled trial. PLoS ONE 15(3): e0229725.
https://doi.org/10.1371/journal.pone.0229725
Editor: Andre Scherag, Universitatsklinikum Jena,
GERMANY
Received: October 15, 2019
Accepted: February 11, 2020
Published: March 4, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0229725
Copyright: © 2020 Eggmann et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The dataset and the
analysis script are available from the “Bern Open
Repository and Information System” database
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
16
24
 
| 
do
wn
lo
ad
ed
: 
16
.3
.2
02
0
immobilisation was the most significant factor associated with weakness at ICU discharge in
the regression models (MRC-SS: -24.57(95%CI [-37.03 to -12.11]); p<0.001).
Conclusions
In this general, critically ill cohort, weakness at ICU discharge was associated with short-
term functional disability and prolonged hospital length of stay, but not with quality of life,
which was equivalent to the values for patients without ICUAW within six months. Immobili-
sation may be a modifiable risk factor to prevent ICUAW. Prospective trials are needed to
validate these results.
Trial registration
German Clinical Trials Register (DRKS) identification number: DRKS00004347, registered
on September 10, 2012.
Introduction
Recent years have seen increased survival rates for severely ill patients admitted to intensive
care units (ICU) [1, 2]. However, long-term functional disability as well as cognitive and men-
tal health impairment are common in ARDS or sepsis survivors [3–6], leading to poor quality
of life and a substantial five-year mortality [7].
Muscle weakness may be a key contributor to the persisting disability of these survivors [8,
9]. However, there is a paucity of data to support a negative impact of ICU-acquired weakness
(ICUAW) on physical functioning [10]. Moreover, ICUAW may also be present in less
severely ill patients [11]. The few studies that investigated functional outcomes in ICUAW sur-
vivors were limited to specific subgroups (e.g. ARDS) [12, 13], lacked performance-based mea-
surements [14–16] or were conducted after the post-acute phase thereby including only the
weakest patients [17]. More research on the physical consequences of ICUAW is therefore
highly needed to advance early treatment and to prevent long-term disability after critical
illness.
Additionally, early identification of persons at risk for ICUAW is necessary for targeted
therapeutic or preventive interventions. Postulated risk factors for ICUAW are multiorgan
failure [18], increased systemic inflammation [19], female sex [20], duration of mechanical
ventilation [21] or bed rest [12]. However, the strength of these risk factors’ association with
ICUAW remains uncertain and requires further investigation [10].
This exploratory study therefore aimed first to investigate functional outcomes at hospital
discharge and health-related quality of life after six months in critically ill patients with severe,
moderate or no ICUAW at ICU discharge, and second to explore the role of early risk factors
for reduced muscle strength at ICU discharge in mechanically ventilated, critically ill adults.
Methods
Design and setting
Data for this secondary analysis were collected as part of a randomised controlled trial that
compared very early endurance training and mobilisation to usual care in mechanically venti-
lated, critically ill adults [22]. The trial was prospectively registered (DRKS00004347) and con-
ducted in the mixed ICU of a large, tertiary academic centre in Switzerland (Department of
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https://github.com/CTU-Bern/FuncAbil_icuaw.
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Study population and management
Eligible participants were older than 18 years, had been independent before the episode of crit-
ical illness and were expected to remain on mechanical ventilation for at least 72 hours. Partici-
pants with pre-existing muscle weakness, preceding hospital stay of more than 10 days
duration, contraindications to cycling, enrolment in another trial, palliative care, diagnoses
that precluded walking at hospital discharge, or insufficient command of German or French
were excluded.
All patients were managed by targeted, light sedation and protocol-guided weaning [23].
Standard ICU care also included a nutrition protocol and regular assessments of energy expen-
diture using indirect calorimetry [24]. Physiotherapy started within 48 hours of ICU admission
with two different exercise regimes that included usual early mobilisation versus early, pro-
gressive endurance and resistance training in addition to usual early mobilisation. All partici-
pants received standard therapy after ICU discharge such as cycling, walking, strengthening,
breathing and functional exercises. Further details on study interventions and procedures have
been published elsewhere [25].
Data collection and measurements
Baseline demographics and clinical characteristics were collected at study enrolment by the
study nurse responsible. Functional measurements were administered by trained physiothera-
pists blinded to initial group allocation. Muscle strength was assessed with the Medical
Research Council sum-score (MRC-SS) at ICU discharge. The MRC-SS evaluates strength in
three bilateral muscles of the upper and lower extremities from 0 (no contraction) to 5 (normal
strength) with a maximal summed score of 60 [26]. A cut-off of less than 48 points was used to
clinically diagnose ICUAW [27]. To further differentiate between moderate and severe weak-
ness, participants who scored less than 36 were considered severely weak [28]. Valid and reli-
able strength assessments are dependent upon sufficient cooperation by the participant [29].
Accordingly, the MRC-SS was only performed in participants who were able to follow at least
3 out of 5 standardised commands [20]. In the case of an ICU re-admission within the same
hospital stay, the last available MRC-SS was used for analysis to account for subsequent weak-
ness. ICU re-admissions were subject to the same study procedures and data collection as
described previously.
The primary functional outcomes for this analysis were chosen as per the original trial:
functional independence evaluated with the Functional Independence Measure (FIM) [30]
and functional capacity assessed with the 6-Minute Walk Test (6MWT) [31] at hospital dis-
charge. Additional secondary outcomes of interest were FIM at ICU discharge, Timed ‘Up &
Go’ [32] at hospital discharge, hospital length of stay and discharge destination, tracheostomy
incidence, ICU readmissions, hospital and 6-month mortality as well as participants’ health-
related quality of life determined with the Short Form 36 (SF-36) [33] six months after hospital
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discharge. We further explored whether functional performance at hospital discharge might
be useful to predict 6-month quality of life. See supporting information for a detailed timetable
(S1 Table).
Statistical analysis
The two randomised groups did not differ with regard to the primary or secondary outcomes,
consequently, we considered the cohort as one single cohort. Patient demographics and char-
acteristics were summarised with descriptive statistics. Continuous data could not be assumed
normally distributed and are therefore presented as medians with interquartile ranges (IQR:
first (25%) quartile to third (75%) quartile). Categorical data are given as numbers with
percentages.
We hypothesised that participants with no ICUAW would achieve better functional perfor-
mance at hospital discharge and a higher quality of life after six months when compared to
participants with moderate to severe ICUAW. The null hypothesis of equal distributions in
functional outcomes for patients diagnosed with no (MRC-SS >48), moderate (MRC-SS 36–
47) or severe ICUAW (MRC-SS <36) was tested against the alternative hypothesis of an
ordered relationship with the Cuzick test [34]. For example, when applying the Cuzick test to
‘6MWT’, the null hypothesis of equal distributions was tested against the following alternative
hypothesis: severe weakness < no weakness and severe weakness�moderate weakness� no
weakness, and when applying the Cuzick test to ‘hospital length of stay’, the alternative hypoth-
esis was severe weakness > no weakness and severe weakness�moderate weakness� no
weakness. In baseline variables the ordered relationship among groups did not make sense,
therefore, the baseline measurements for the three MRC-SS groups were compared with the
non-parametric Kruskal-Wallis test. Categorical data were analysed with Pearson’s Chi-
Squared test. Baseline characteristics of participants with complete versus missing MRC-SS
values were investigated for baseline differences because of the prerequisite of cooperation for
a valid MRC-SS assessment. Correlations were investigated with non-parametric Spearman
correlation coefficients. Considering the aims of this analysis, multiple imputations were not
performed as expected extrapolation would have been applied to patients who died or were
unable to follow commands and thus unable to be functionally active. However, to account for
the limited sample size, we conducted a sensitivity analysis to compare the data of participants
without ICUAW to the pooled data of participants with severe and moderate ICUAW with the
non-parametric Mann-Whitney-U tests for between-group comparisons.
The ICU risk factors for muscle weakness at ICU discharge to be explored were identified
from previous evidence [35] and chosen based on the available data by favouring uncorrelated
risk factors. We assumed that our analysis would reveal some influence of the chosen risk fac-
tors for reduced muscle strength at ICU discharge regardless of initial randomisation. To
avoid overfitting, we restricted the factors to six (with a rule of thumb of a minimum 10 obser-
vations per factor [36]): Sequential Organ Failure Assessment (SOFA) at study inclusion [18,
19], gender [20], length of ICU stay [37], previous limitation in activities of daily living (ADL)
[38], mobility level in the ICU (in-bed, edge-of-bed, out-of-bed) [12], and initial randomisa-
tion group (control or experimental) in order to exclude a confounding effect. We investigated
the effect of all risk factors on MRC-SS as crude (with simple linear regression) and adjusted
for the totality of considered factors (with multivariable linear regression). Two sensitivity
analyses were conducted with all listed risk variables excluding either randomisation group
(potential confounder) or previous ADL limitation (due to missing data).
Data analysis was performed with R version 3.5.3 (2019-03-11) and SPSS (IBM SPSS Statis-
tics Version Premium GradPack 24). The level of significance was set at p<0.05 (two-tailed).
PLOS ONE Outcomes and risk for ICUAW
PLOS ONE | https://doi.org/10.1371/journal.pone.0229725 March 4, 2020 4 / 16
Due to the exploratory nature of this analysis, we decided a priori that the significance thresh-
old would not be adjusted for multiple testing.
Results
Of the 115 participants who were enrolled in the randomised controlled trial, 83 (72%) com-
pleted an MRC-SS at ICU discharge (Fig 1). Main reasons for missing MRC-SS values were
ICU-death (14%) and patients’ inability to follow commands (11%), while 5 patients (4%)
were missed for follow-up at ICU discharge. Among the assessed patients, ICUAW was com-
mon with 17 (20%) severe, 32 (39%) moderate, and 34 (41%) no weakness, respectively. The
patients in the three MRC-SS groups did not differ significantly in their baseline demographics
and characteristics, except for a higher prevalence of liver disease in the severely weak group
(Table 1). In contrast, participants with missing MRC-SS values differed in respect to
APACHE II scores (completed 21 [IQR 17–26]; missing 27 [21.5–30]), SOFA (completed 8
[6–10]; missing 10 [8 to14.25]), and frequency of liver disease (completed 7 (9%); missing 8
(26%)) (S2 Table and S3 Table).
Functional outcomes, hospital variables and quality of life
The differences between severe, moderate and no weakness for the primary and secondary
outcomes are presented in Table 2. Weakness at ICU discharge was significantly associated
with functional disability at hospital discharge and subsequent length of hospital stay, but not
with health-related quality of life after six months. The distribution between the three MRC-SS
groups for the two primary outcomes is illustrated in Fig 2, rejecting the null-hypothesis of
equal distributions. Thus, for both 6MWT and FIM participants with ‘severe weakness’ per-
formed less well compared to ‘no weakness’, performance in ‘severe weakness’ was similar or
worse to ‘moderate weakness’, which was also similar to or worse than ‘no weakness’. The
achieved percentages of age-predicted values for the 6MWT were also significantly different
(p = 0.006: Cuzick test) with 36% (IQR 19–65), 55% (IQR 25–94) and 74% (IQR 39–89) of
Fig 1. Study flow.
https://doi.org/10.1371/journal.pone.0229725.g001
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predicted normative values [39] for severe, moderate and no weakness, respectively. Fig 3 fur-
ther illustrates the distribution between the three MRC-SS groups for the Timed ‘Up & Go’
test and hospital length of stay after ICU discharge, while Fig 4 illustrates the distribution for
the SF-36 physical and mental health sum-scores. Sensitivity analysis comparing all partici-
pants with ICUAW versus non-ICUAW similarly confirmed a significant association of
ICUAW with functional disability and prolonged hospital stay, and lack of association with
6-month health-related quality of life (S4 Table). Functional performance at hospital discharge
Table 1. Baseline demographics for participants with complete MRC-SS assessment.
Variables n All with complete
MRC-SS
n Severe weakness
(MRC-SS <36)
n Moderate weakness
(MRC-SS 36–48)
n No weakness
(MRC-SS >48)
p-
value
ICUAW incidence (MRC-SS<48) 83 49 (59%) 17 17 (100%) 32 32 (100%) 34 0 (0%)
MRC-SS at ICU discharge (0–60) 83 45 [38.5–54] 17 26 [20–31] 32 42 [40–45] 34 55.5 [50–58]
Randomized to non-standard
intervention
83 40 (48%) 17 11 (65%) 32 12 (38%) 34 17 (50%) 0.186
Age (years) 83 67.5 [55.55–75.4] 17 68.1 [65.3–74.9] 32 67.85 [55.9–74.75] 34 60.75 [45.08–76.3] 0.284
Gender (male) 83 52 (63%) 17 9 (53%) 32 17 (53%) 34 26 (76%) 0.095
BMI (kg/m2) 83 26.2 [23.6–31.35] 17 27.8 [22.2–34] 32 27 [23.98–29.85] 34 25.65 [23.9–31.5] 0.984
Weight (kg) 83 80 [66–90] 17 85 [62–95] 32 79.2 [66.5–85] 34 80 [68.25–90] 0.783
APACHE II score (0–71) a 83 21 [17–26] 17 23 [18–26] 32 21.5 [18–26.25] 34 20 [16.25–23.75] 0.483
SOFA score (0–24) b 83 8 [6–10] 17 9 [7–10] 32 8 [7–10.25] 34 6.5 [5–10] 0.065
ICU days until study inclusion 83 1.71 [0.85–2.57] 17 1.76 [1.24–2.63] 32 1.84 [1.05–2.61] 34 1.51 [0.8–2.08] 0.518
ICU length of stay at original
hospital (days)
83 5.93 [4.43–10.26] 17 6.23 [4.73–14.35] 32 6.56 [4.28–11.88] 34 5.63 [3.50–7.89] 0.210
ICU diagnosis on ICU admission
Gastroenterology 83 11 (13%) 17 2 (12%) 32 6 (19%) 34 3 (9%) 0.680
Heart surgery 18 (22%) 5 (29%) 6 (19%) 7 (21%)
Hemodynamic insufficiency 16 (19%) 3 (18%) 6 (19%) 7 (21%)
Neurology / neurosurgery 4 (5%) 1 (6%) 1 (3%) 2 (6%)
Other 1 (1%) 0 (0%) 0 (0%) 1 (3%)
Other surgery 11 (13%) 3 (18%) 4 (12%) 4 (12%)
Respiratory insufficiency 20 (24%) 2 (12%) 9 (28%) 9 (26%)
Trauma 2 (2%) 1 (6%) 0 (0%) 1 (3%)
Comorbidities on ICU admission
Restricted in activities of daily
living (ADL)
80 8 (10%) 16 3 (19%) 32 4 (12%) 32 1 (3%) 0.196
NYHA symptoms (stage 2 to 4) 80 36 (45%) 16 6 (38%) 32 18 (56%) 32 12 (38%) 0.256
Dyspnoea symptoms 80 20 (25%) 16 2 (12%) 32 7 (22%) 32 11 (34%) 0.223
Hematologic malignancy 80 3 (4%) 16 0 (0%) 32 0 (0%) 32 3 (9%) 0.097
Immuno-suppression 80 11 (14%) 16 3 (19%) 32 3 (9%) 32 5 (16%) 0.622
Liver disease 80 7 (9%) 16 4 (25%) 32 2 (6%) 32 1 (3%) 0.033
Chronic dialysis 80 0 (0%) 16 0 (0%) 32 0 (0%) 32 0 (0%)
a at ICU admission
b at study inclusion
Data are presented as median [IQR 25% - 75%] or frequencies (%). Analysis for continuous variables was performed with the Kruskal–Wallis test for the null hypothesis
of equal distributions in the three groups, and for categorical and binary variables with Pearson’s Chi-Squared test with the null hypothesis of independence between the
tested condition and MRC-SS groups.
Abbreviations: NYHA = New York Heart Association, BMI = Body Mass Index, APACHE = Acute Physiology and Chronic Health Evaluation, SOFA = Sequential
Organ Failure Assessment
https://doi.org/10.1371/journal.pone.0229725.t001
PLOS ONE Outcomes and risk for ICUAW
PLOS ONE | https://doi.org/10.1371/journal.pone.0229725 March 4, 2020 6 / 16
was not associated with quality of life (S5 Table). Hospital discharge destinations did not sig-
nificantly differ between the three MRC-SS groups (p = 0.321): Severely weak patients (n = 17)
were predominantly discharged to a rehabilitation facility (65%), moderately weak patients
(n = 32) to rehabilitation (47%) or an external hospital (25%) and non-weak participants
(n = 34) to rehabilitation (53%) or home (29%). Similarly, there was no difference in the
MRC-SS groups for ICU readmissions (p = 0.264), tracheostomy incidence (p = 0.630) or hos-
pital and 6-month mortality (p = 0.362).
Risk factors
Table 3 presents the ICU risk factors that were significantly associated with ICUAW at ICU
discharge. In-bed immobilisation and female gender remained significantly associated with
low MRC-SS scores in sensitivity analyses (S6 Table). When the ADL variable was removed
from the model due to the reduced sample size, length of ICU stay became marginally associ-
ated with MRC-SS (-0.28 95%-CI [-0.55 to -0.01], p = 0.049).
Table 2. Primary and secondary outcome-comparisons per MRC-SS group.
Variable n All with complete
MRC-SS
n Severe weakness n Moderate weakness n No weakness p-value
Primary outcomes at hospital discharge
6MWT (m) 73 185 [95–320] 17 110 [75–240] 28 196 [90–324.25] 28 222.5 [129–378.75] 0.013
FIM (18–126) 73 110 [92–119] 17 91 [68–101] 27 113 [102.5–118.5] 29 112 [97–123] 0.001
Secondary ICU and hospital outcomes
FIM at ICU discharge (18–126) 83 36 [26.5–47.5] 17 24 [21–34] 32 31 [26.5–46] 34 41.5 [35–57.5] <0.001
Timed ‘Up & Go ‘test (s) at hospital discharge 57 19 [11.4–25] 14 23.25 [20.25–34] 21 18.7 [12.6–27] 22 14 [8–23.25] 0.013
Hospital length of stay after ICU discharge
(days)
83 16.87 [11.16–26.92] 17 20.9 [15.83–
30.73]
32 16.86 [13.07–27.10] 34 11.16 [7.35–19.74] 0.008
SF-36: quality of life after 6 months
Physical functioning (0–100) 54 75 [46.25–85] 14 72.5 [55–80] 15 70 [37.5–85] 25 75 [45–90] 0.449
Role physical (0–100) 52 25 [0–50] 13 50 [25–75] 14 25 [0–43.75] 25 25 [0–50] 0.583
Bodily pain (0–100) 54 74 [51.25–100] 14 77 [53.75–100] 15 70 [41–92] 25 80 [62–100] 0.595
General health (0–100) 52 61 [45.75–73.25] 14 58.5 [47–70.75] 13 50 [40–57] 25 67 [52–77] 0.164
Vitality (0–100) 53 55 [40–70] 14 60 [51.25–73.75] 14 50 [30–55] 25 55 [50–70] 0.640
Social functioning (0–100) 53 75 [50–100] 14 87.5 [53.12–100] 14 75 [53.12–96.88] 25 75 [62.5–100] 0.982
Role emotional (0–100) 52 66.67 [33.33–100] 12 100 [33.33–100] 15 33.33 [0–83.34] 25 100 [33.33–100] 0.795
Mental health (0–100) 52 76 [68–85] 14 82 [69–87] 14 70 [61–79] 24 82 [71–88] 0.659
Physical health (sum-score) 49 42.6 [34.76–48.23] 12 43.19 [33.11–
48.5]
13 42.92 [27.67–47.39] 24 42.18 [36.49–
48.75]
0.874
Mental health (sum-score) 49 50.09 [44.4–56.19] 12 51.3 [44.56–
58.08]
13 48 [37.67–51.08] 24 51.86 [46.18–
56.19]
0.908
Data are presented as median [IQR 25% - 75%] or frequencies (%). Only effectively measured data were analysed. Categorical and binary variables testing was
performed with Pearson’s Chi-Squared test (the null hypothesis is independence between the tested condition and the MRC-SS groups). Continuous variables testing
was performed with the non-parametric Cuzick test (the null hypothesis is equal distributions in the three groups against the alternative non-inferiority or non-
superiority). SF-36 (version 2): worst score: 0, best score: 100, sum-score: T-values where the population mean is 50 and the SD is 10; based on US-population 1990.
German norm-based (1994) standardized sum-scores (T-values) for SF-36 were similar to the US-population (data shown in sensitivity analysis in S4 Table).
Abbreviations: 6MWT = 6-Minute Walk Test, FIM = Functional Independence Measure, SF-36 = Short Form 36 questionnaire
https://doi.org/10.1371/journal.pone.0229725.t002
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Discussion
In this secondary analysis, participants without ICUAW at ICU discharge had better func-
tional outcomes at hospital discharge with shorter length of hospital stays when compared to
participants with moderate and, especially, severe ICUAW. However, contrary to our hypothe-
sis, quality of life after six months was similar in participants with severe, moderate or no
ICUAW and not associated with functional performance in the hospital. While mental health
sum-scores reached normative values, physical health sum-scores continued to be reduced in
all three MRC-SS groups. The risk factor most associated with weakness at ICU discharge was
in-bed immobilisation. Female gender or reduced mobility levels were further risk factors of
ICUAW. These results provide useful information about the functional ability and subsequent
health-related quality of life in a general, mechanically ventilated ICU population after a criti-
cal illness period, but need to be validated in prospective studies.
There are few available studies with which to compare our findings on the functional out-
comes of ICUAW patients at hospital discharge. Hermans et al. [14] reported no difference in
the 6MWT in matched weak and non-weak patients. However, high dropout rates limited this
conclusion and results were not confirmed in sensitivity analyses. Although not performed at
hospital discharge, Fan et al. [12] investigated the 6MWT over 24 months in ARDS patients.
After three months, they found no difference between ICUAW versus non-ICUAW patients,
yet for all later time-points, the distance walked was significantly shorter in participants with
Fig 2. Illustration of the two primary outcomes per MRC-SS group. Illustration of the 6MWT (a) and the FIM (b) at hospital discharge with non-parametric Cuzick
test clearly rejecting the null hypothesis in favour of alternative: values for severe weakness< no weakness and for severe weakness�moderate weakness vales� no
weakness.
https://doi.org/10.1371/journal.pone.0229725.g002
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ICUAW. Sidiras et al. [40] also described significant differences of the FIM at hospital dis-
charge in ICUAW versus non-ICUAW patients. Yet, while values for non-ICUAW patients
were comparable to our results, ICUAW patients were substantially less independent in their
study (65 [IQR 53–87] in [40] versus 105.5 [88.5–117.5]). This might explain their results for
3- and 6-month follow-up, which were also significantly lower in participants with ICUAW,
whereas our patients showed similar health-related quality of life. Overall our findings rein-
force the rather weak evidence that ICUAW is associated with functional disability which may
lead to less independence at hospital discharge. In turn, loss of independence might be the
cause of prolonged length of hospital stays and increased health-care costs for patients with
ICUAW [14], emphasising the need to make recovery a priority in acute care [41].
When comparing our results for health-related quality of life with the existing literature, we
found some discrepancies. For example, weak and non-weak ARDS survivors differed signifi-
cantly in their SF-36 physical function sum-scores at six months in a US cohort study [12].
Similarly, a Dutch study [15] reported significant differences in the SF-36 domain ‘physical
functioning’ between ICUAW (45 [IQR 30–70]) and non-ICUAW (75 [50–90]) in participants
from a general ICU population. In our study, regardless of initial weakness, participants pre-
sented with similar median values in the ‘physical functioning’ domain (ICUAW 70 [IQR 50–
80] versus non-ICUAW 75 [45–90], p = 0.375) as the participants without ICUAW in the
Dutch study [15]. Finally, in a Greek trial, participants with ICUAW scored significantly lower
Fig 3. Illustration of the Timed ‘Up & Go’ test and hospital length of stay per MRC-SS group. Illustration of the Timed ‘Up & Go’ test (a) and hospital length of stay
after ICU discharge (b) with non-parametric Cuzick test clearly rejecting the null hypothesis in favour of alternative: values for severe weakness> no weakness and severe
weakness�moderate weakness� no weakness.
https://doi.org/10.1371/journal.pone.0229725.g003
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in the SF-36 domains of ‘general health’, ‘pain’, ‘physical functioning’ and ‘role physical’ than
non-ICUAW [40]. The apparent recovery of the very weak patients in our study was therefore
surprising and may imply a different pathway of recovery between countries. However, we
could not distinguish a difference in discharge destinations between the three MRC-SS groups.
Alternatively, our population might have been more responsive to recovery. Herridge et al.
[42] describe four disability subtypes based on the FIM seven days after ICU discharge as well
as by age and length of ICU stay. These four subtypes determined a 1-year trajectory of recov-
ery. We cannot directly compare the FIM due to the different time-points of the measurement
(36 at ICU discharge in our cohort versus 54 one week after ICU discharge in [42]). However,
when comparing baseline characteristics, we suspect that the shorter length of ICU stay in our
cohort (5.9 versus 19.0 days in [42]), despite being slightly older (68 years versus 58 in [42]),
might have been beneficial for recovery. Our results might also have been confounded by non-
responders who might have been too ill to return the questionnaire or influenced by false nega-
tive results especially in the ‘role physical’ domain where severely weak patients (50 [IQR 25–
75]) had surprisingly higher values than non-weak patients (25 [0–50]). Lastly, our sample
might have been too small and selective to reveal a relevant association of ICUAW with quality
of life.
Although the investigated risk factors were not inclusive of all previously known contribu-
tors to ICUAW [35], they support the findings of Fan et al. [12] who found that with every day
Fig 4. Illustration of the SF-36 physical and mental health sum-scores per MRC-SS group. Illustration of the SF-36 physical health sum-score (a) and mental health
sum-score (b) with non-parametric Cuzick test accepting the null hypothesis of equal distributions.
https://doi.org/10.1371/journal.pone.0229725.g004
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of bed rest muscle strength is reduced by 3–11% in critically ill ARDS patients. In-bed immo-
bilisation is a largely modifiable risk factor [43] and might be targeted with therapeutic inter-
ventions in critically ill patients at risk. However, current evidence on the benefit of early
mobilisation is conflicting and needs further study [44]. Our randomised controlled trial like-
wise failed to reveal a superior intervention to increase strength at ICU discharge when com-
paring two different exercise regimes [22]. However, early mobilisation was part of both trial
arms and thus not under direct investigation. Overall, more research is needed on how to over-
come this exposure outcome overlap and what kind of intervention should be prescribed. The
influence of female gender on muscle strength has also previously been described [20] and
might be a result of reduced muscle mass in women [35]. As a consequence, women might
need different treatment from men. This could include early screening to identify weakness
and might mean a prolonged or more intensive period of rehabilitation.
The strength of this study lies in the performance-based measurements—performed by
trained physiotherapists—in a general ICU population with a high ICUAW incidence and
adds relevant information about the functional short-term outcomes in generally, critically ill
patients. Furthermore, the 6-month timeframe has a high clinical relevance because health-
related quality of life appears to plateau after this period [45]. There are also several limitations.
First, this secondary analysis was limited by the availability of the existing data and we did not
adjust the significance threshold for multiple comparisons. Accordingly, additional risk factors
may have remained undiscovered or the identified factors may have been a random associa-
tion. Second, a rather high drop-out rate at six months (41%) substantially limits the possible
conclusions about these patients’ subsequent quality of life. Third, generalisability is limited
Table 3. Univariate (crude) and multivariate (adjusted) regression models for chosen ICU risk factors with MRC-SS as response.
n Crude effect (95% CI) p-value n Adjusted effect (95% CI) p-value
Gender
female Reference Reference
male 83 6.94 (1.61 to 12.27) 0.013 80 5.51 (0.64 to 10.38) 0.030
Group allocation
control group Reference Reference
experimental group 83 -2.02 (-7.37 to 3.33) 0.461 80 -0.66 (-5.60 to 4.28) 0.794
Illness severity
SOFA score 83 -0.63 (-1.37 to 0.10) 0.094 80 -0.55 (-1.27 to 0.17) 0.141
Length of ICU stay
Length of ICU stay at original hospital (days) 83 -0.21 (-0.48 to 0.06) 0.126 80 -0.26 (-0.53 to 0.01) 0.065
Activities of daily living (ADL)
Not restricted in ADL Reference Reference
Restricted in ADL 80 -5.38 (-14.33 to 3.58) 0.243 80 -6.18 (-13.97 to 1.61) 0.124
Mobilisation level in ICU
Mobilisation level in ICU: out-of-bed a Reference Reference
Mobilisation level in ICU: in-bed 83 -23.80 (-37.05 to -10.54) 0.001 80 -24.57 (-37.03 to -12.11) <0.001
Mobilisation level in ICU: edge-of-bed 83 -6.89 (-12.22 to -1.55) 0.013 80 -7.20 (-12.78 to -1.62) 0.014
a Overall p values for the factor “mobilisation level in the ICU” with Omnibus test: p = 0.001 for crude and p<0.001 for adjusted effect
Significance of the chosen variables in two regression models with MRC-SS as response. Crude regression is just response (MRC-SS) and corresponding explanatory
variable. Adjusted regression includes all listed explanatory variables. The robust estimations give the same results with non-significant bias’ tests (with the null:
presence of the bias due to lack of robustness or outlying observations). None of the terms revealed non-linearity when fitting a regression model allowing non-linear
dependence (via penalized splines) on explanatory variables. For full regression-output see supporting information (S1 File).
Abbreviations: SOFA = Sequential Organ Failure Assessment, ADL = activities of daily living
https://doi.org/10.1371/journal.pone.0229725.t003
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due to a selective and single-centre sample. Fourth, while it seemed that patients with ICUAW
recovered, this observational study can draw no conclusions about possible interventions.
Given that post-ICU rehabilitation presently lacks evidence to improve quality of life [46], the
pathways of recovery need further investigation. A prospective mixed-methods cohort study
might reveal possible interventions to target for future studies. Fifth, we may have underesti-
mated the incidence of ICUAW because participants that could not be tested due to their
inability to follow commands may have scored as weak or functionally impaired. The recom-
mended cut-offs for a clinical ICUAW diagnosis as applied here are further limited by the
absence of proper validation and the lack of a gold standard. For these reasons, to fully under-
stand the consequences of ICUAW, more research on the diagnosis of ICUAW is needed.
Finally, the retrospective and exploratory nature of our analysis requires further investigation.
To the best of our knowledge, there are no publicly available datasets to validate our results on
ICUAW risk factors or the functional outcome of patients after an ICUAW diagnosis. Our
results should therefore be validated in a prospective, longitudinal observational study with
long-term follow-up.
Conclusions
Participants without ICUAW had superior functional performance at hospital discharge and
shorter length of hospital stays when compared to participants with ICUAW. The increased
strength was associated with early out-of-bed mobilisations during the ICU. However, after six
months, participants with ICUAW reached similar health-related quality of life to participants
without ICUAW at ICU discharge. This implies that recovery for critically ill, mechanically
ventilated patients with ICUAW might be at least partly achieved. Nevertheless, these findings
need to be validated in a prospective cohort study.
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